Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel plus capecitabine vs oxaliplatin plus capecitabine as adjuvant chemotherapy after D2 gastrectomy for gastric cancer
ChiCTR2000034770Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jul 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in gastric adenocarcinoma comparing docetaxel plus capecitabine with oxaliplatin plus capecitabine (2 arms). Primary endpoint: disease-free survival. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
docetaxelcapecitabineoxaliplatin
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2000034770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034770.